Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles

Esophageal cancer is the sixth most common cause of cancer-related death worldwide. Peptide modified nanoparticles have been engineered as novel strategies to improve esophageal adenocarcinoma (EAC) therapy. This study aimed to develop a trastuzumab (TAB) modified system for the delivery of cisplati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Qingxia, Wang, Jiancheng, Liu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598994/
https://www.ncbi.nlm.nih.gov/pubmed/33118428
http://dx.doi.org/10.1080/10717544.2020.1837294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598994/
https://www.ncbi.nlm.nih.gov/pubmed/33118428
http://dx.doi.org/10.1080/10717544.2020.1837294

Ejemplares similares